$12.93
Insights on Elanco Animal Health Inc
Revenue is down for the last 2 quarters, 1.06B → 1.03B (in $), with an average decrease of 3.1% per quarter
Netprofit is up for the last 2 quarters, -1.09B → -141.0M (in $), with an average increase of 677.3% per quarter
In the last 3 years, Neurocrine Biosciences Inc. has given 38.2% return, outperforming this stock by 96.3%
1.55%
Downside
Day's Volatility :3.45%
Upside
1.93%
39.06%
Downside
52 Weeks Volatility :53.32%
Upside
23.4%
Period | Elanco Animal Health Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -12.16% | -0.4% | 0.0% |
6 Months | 42.09% | 9.6% | 0.0% |
1 Year | 27.14% | 3.9% | -1.3% |
3 Years | -58.13% | 12.8% | -22.1% |
Market Capitalization | 6.4B |
Book Value | $12.63 |
Earnings Per Share (EPS) | -2.5 |
PEG Ratio | 1.84 |
Wall Street Target Price | 17.75 |
Profit Margin | -27.87% |
Operating Margin TTM | 1.64% |
Return On Assets TTM | 1.39% |
Return On Equity TTM | -18.22% |
Revenue TTM | 4.4B |
Revenue Per Share TTM | 8.97 |
Quarterly Revenue Growth YOY | 5.1% |
Gross Profit TTM | 2.5B |
EBITDA | 973.0M |
Diluted Eps TTM | -2.5 |
Quarterly Earnings Growth YOY | 1.1 |
EPS Estimate Current Year | 0.92 |
EPS Estimate Next Year | 1.06 |
EPS Estimate Current Quarter | 0.11 |
EPS Estimate Next Quarter | 0.3 |
What analysts predicted
Upside of 37.28%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 3.1B | ↑ 6.15% |
Net Income | 86.5M | ↓ 127.84% |
Net Profit Margin | 2.82% | ↑ 13.57% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 3.1B | ↑ 0.14% |
Net Income | 67.9M | ↓ 21.5% |
Net Profit Margin | 2.21% | ↓ 0.61% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 3.3B | ↑ 6.59% |
Net Income | -560.1M | ↓ 924.89% |
Net Profit Margin | -17.11% | ↓ 19.32% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 4.8B | ↑ 45.57% |
Net Income | -472.0M | ↓ 15.73% |
Net Profit Margin | -9.91% | ↑ 7.2% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 4.4B | ↓ 7.28% |
Net Income | -74.0M | ↓ 84.32% |
Net Profit Margin | -1.67% | ↑ 8.24% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 4.4B | ↓ 0.02% |
Net Income | -1.2B | ↑ 1563.51% |
Net Profit Margin | -27.87% | ↓ 26.2% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.0B | ↓ 12.66% |
Net Income | -49.0M | ↑ 122.73% |
Net Profit Margin | -4.77% | ↓ 2.9% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 988.0M | ↓ 3.89% |
Net Income | -54.0M | ↑ 10.2% |
Net Profit Margin | -5.47% | ↓ 0.7% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.3B | ↑ 27.23% |
Net Income | 103.0M | ↓ 290.74% |
Net Profit Margin | 8.19% | ↑ 13.66% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.1B | ↓ 15.91% |
Net Income | -97.0M | ↓ 194.17% |
Net Profit Margin | -9.18% | ↓ 17.37% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.1B | ↑ 1.04% |
Net Income | -1.1B | ↑ 1029.9% |
Net Profit Margin | -102.62% | ↓ 93.44% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.0B | ↓ 3.09% |
Net Income | -141.0M | ↓ 87.14% |
Net Profit Margin | -13.62% | ↑ 89.0% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 9.0B | ↑ 0.18% |
Total Liabilities | 3.8B | ↑ 227.03% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 9.0B | ↑ 0.32% |
Total Liabilities | 3.4B | ↓ 8.52% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 17.7B | ↑ 96.9% |
Total Liabilities | 9.2B | ↑ 168.02% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 16.5B | ↓ 6.84% |
Total Liabilities | 8.9B | ↓ 2.95% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 15.5B | ↓ 6.02% |
Total Liabilities | 8.2B | ↓ 8.31% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 14.4B | ↓ 7.29% |
Total Liabilities | 8.1B | ↓ 0.77% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 14.9B | ↓ 4.19% |
Total Liabilities | 8.2B | ↓ 3.05% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 15.5B | ↑ 3.63% |
Total Liabilities | 8.2B | ↓ 0.01% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 15.8B | ↑ 1.79% |
Total Liabilities | 8.3B | ↑ 1.06% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 15.8B | ↑ 0.17% |
Total Liabilities | 8.4B | ↑ 1.05% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 14.3B | ↓ 9.19% |
Total Liabilities | 8.2B | ↓ 1.98% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 14.4B | ↑ 0.13% |
Total Liabilities | 8.1B | ↓ 0.86% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 487.3M | ↑ 180.38% |
Investing Cash Flow | -127.0M | ↓ 86.83% |
Financing Cash Flow | -35.2M | ↓ 104.15% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 224.1M | ↓ 54.01% |
Investing Cash Flow | -234.8M | ↑ 84.88% |
Financing Cash Flow | -304.8M | ↑ 765.91% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -41.0M | ↓ 118.3% |
Investing Cash Flow | -4.8B | ↑ 1935.43% |
Financing Cash Flow | 5.0B | ↓ 1725.3% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 483.0M | ↓ 1278.05% |
Investing Cash Flow | -530.0M | ↓ 88.91% |
Financing Cash Flow | 210.0M | ↓ 95.76% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 452.0M | ↓ 6.42% |
Investing Cash Flow | -179.0M | ↓ 66.23% |
Financing Cash Flow | -549.0M | ↓ 361.43% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 189.0M | ↓ 39.42% |
Investing Cash Flow | -37.0M | ↑ 0.0% |
Financing Cash Flow | -169.0M | ↑ 76.04% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 13.0M | ↓ 93.12% |
Investing Cash Flow | -76.0M | ↑ 105.41% |
Financing Cash Flow | -84.0M | ↓ 50.3% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -145.0M | ↓ 1215.38% |
Investing Cash Flow | -55.0M | ↓ 27.63% |
Financing Cash Flow | 174.0M | ↓ 307.14% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 61.0M | ↓ 142.07% |
Investing Cash Flow | -43.0M | ↓ 21.82% |
Financing Cash Flow | 39.0M | ↓ 77.59% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 198.0M | ↑ 224.59% |
Investing Cash Flow | -36.0M | ↓ 16.28% |
Financing Cash Flow | -157.0M | ↓ 502.56% |
Sell
Neutral
Buy
Elanco Animal Health Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Elanco Animal Health Inc | -18.73% | 42.09% | 27.14% | -58.13% | -59.12% |
Neurocrine Biosciences Inc. | -4.7% | 23.86% | 29.07% | 38.18% | 65.61% |
Haleon Plc Spon Ads | -0.83% | 1.09% | -6.49% | 12.82% | 12.82% |
Zoetis Inc. | -13.27% | -12.59% | -17.47% | -14.66% | 42.73% |
Viatris Inc. | -4.9% | 26.12% | 20.58% | -15.79% | -31.15% |
Catalent, Inc. | -0.62% | 32.76% | 24.72% | -51.21% | 26.1% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Elanco Animal Health Inc | NA | NA | 1.84 | 0.92 | -0.18 | 0.01 | NA | 12.63 |
Neurocrine Biosciences Inc. | 53.44 | 53.44 | 0.44 | 4.78 | 0.13 | 0.09 | NA | 22.61 |
Haleon Plc Spon Ads | 29.36 | 29.36 | 1.69 | 0.45 | 0.07 | 0.04 | 0.03 | 1.8 |
Zoetis Inc. | 28.82 | 28.82 | 2.58 | 5.8 | 0.5 | 0.13 | 0.01 | 10.9 |
Viatris Inc. | 222.4 | 222.4 | NA | 2.78 | 0.0 | 0.03 | 0.04 | 17.05 |
Catalent, Inc. | 211.02 | NA | 2.06 | 0.48 | -0.3 | -0.01 | NA | 20.41 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Elanco Animal Health Inc | Buy | $6.4B | -59.12% | NA | -27.87% |
Neurocrine Biosciences Inc. | Buy | $13.3B | 65.61% | 53.44 | 13.23% |
Haleon Plc Spon Ads | Buy | $37.5B | 12.82% | 29.36 | 9.28% |
Zoetis Inc. | Buy | $66.8B | 42.73% | 28.82 | 27.43% |
Viatris Inc. | Hold | $13.2B | -31.15% | 222.4 | 0.35% |
Catalent, Inc. | Hold | $10.0B | 26.1% | 211.02 | -31.77% |
Dodge & Cox
PRIMECAP Management Company
Vanguard Group Inc
BlackRock Inc
Black Creek Investment Management Inc
T. Rowe Price Associates, Inc.
Elanco Animal Health Inc’s price-to-earnings ratio stands at None
Read Moreelanco is a global animal health company. our vision: food and companionship enriching life. elanco fulfills this vision through three primary pursuits: - helping deliver a safe, more affordable, more abundant food supply by improving the health and performance of animals - helping pets live longer, healthier, higher-quality lives - improving food safety elanco employees are empowered to preserve elanco’s common culture of humility, discipline and involvement. we have a responsibility to connect and contribute to our cause, to be passionate about delivering solutions and value to our customers, and to embrace opportunities for personal and professional growth and development. through innovative products, quality systems and a shared vision, elanco strives daily to enhance animal health—and enrich the lives of people worldwide.
Organization | Elanco Animal Health Inc |
Employees | 9300 |
CEO | Mr. Jeffrey N. Simmons |
Industry | Process Industries |
Cg Oncology Inc.
$12.93
-0.15%
Taiwan Msci Etf Ishares
$12.93
-0.15%
Sl Green Realty Corp.
$12.93
-0.15%
Lg Display Co., Ltd.
$12.93
-0.15%
Willscot Mobile Mini Holding
$12.93
-0.15%
Nnn Reit Inc.
$12.93
-0.15%
Cerevel Therapeutics Holdings Inc
$12.93
-0.15%
Spdr S&p 400 Mid Cap Value E
$12.93
-0.15%
Vanguard Russell 1000 Etf
$12.93
-0.15%